Free Trial

Town & Country Bank & Trust CO dba First Bankers Trust CO Grows Position in Stryker Corporation $SYK

Stryker logo with Medical background

Key Points

  • Town & Country Bank & Trust CO increased its holdings in Stryker Corporation by 14.4% during Q2, bringing their total shares to 9,437, valued at approximately $3.73 million.
  • Stryker has a current consensus target price of $430.33 and a significant number of analysts have rated it as a Moderate Buy.
  • The company declared a quarterly dividend of $0.84 per share, with a rounded annualized dividend yield of 0.9%, payable on October 31st.
  • Five stocks we like better than Stryker.

Town & Country Bank & Trust CO dba First Bankers Trust CO boosted its position in Stryker Corporation (NYSE:SYK - Free Report) by 14.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,437 shares of the medical technology company's stock after acquiring an additional 1,191 shares during the quarter. Stryker accounts for about 1.4% of Town & Country Bank & Trust CO dba First Bankers Trust CO's holdings, making the stock its 20th biggest holding. Town & Country Bank & Trust CO dba First Bankers Trust CO's holdings in Stryker were worth $3,734,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in SYK. Mogy Joel R Investment Counsel Inc. grew its stake in shares of Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after purchasing an additional 3,218 shares in the last quarter. Ferguson Wellman Capital Management Inc. raised its stake in Stryker by 1.9% in the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after buying an additional 3,341 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in Stryker during the 1st quarter worth about $1,840,000. Mar Vista Investment Partners LLC boosted its position in shares of Stryker by 10.2% during the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after acquiring an additional 8,353 shares in the last quarter. Finally, United Services Automobile Association acquired a new position in shares of Stryker during the 1st quarter worth about $2,857,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the topic of several research analyst reports. Truist Financial set a $415.00 target price on Stryker and gave the stock a "hold" rating in a research report on Monday, August 4th. Rothschild & Co Redburn began coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a "neutral" rating and a $420.00 price target on the stock. Rothschild Redb upgraded shares of Stryker to a "hold" rating in a research report on Thursday, September 18th. Needham & Company LLC upped their target price on shares of Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a report on Friday, August 1st. Finally, BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Fourteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $430.33.

Get Our Latest Analysis on Stryker

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the business's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by insiders.

Stryker Trading Up 0.5%

NYSE:SYK opened at $378.70 on Tuesday. The stock has a market capitalization of $144.78 billion, a price-to-earnings ratio of 50.16, a PEG ratio of 2.71 and a beta of 0.93. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The stock has a fifty day moving average price of $387.26 and a two-hundred day moving average price of $379.05. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. During the same period in the prior year, the company posted $2.81 EPS. The business's revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

See Also

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stryker Right Now?

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.